HCPCS code J7604 – Acetylcysteine, inhalation solution

Key takeaways

HCPCS code J7604 covers acetylcysteine inhalation solution, compounded product, administered through DME, unit dose form, per gram.

Medicare does not pay J7604. LCD L33370 denies compounded inhalation solutions as not reasonable and necessary, so no fee schedule rate exists.

No diagnosis rescues the claim. Policy Article A52466 lists J7604 under codes that do not support medical necessity, for all ICD-10 codes.

J7608 is the payable acetylcysteine code. It covers the FDA-approved, non-compounded unit dose product, capped at 74 grams a month.

J7609 is compounded albuterol rather than acetylcysteine, so it does not belong in an acetylcysteine crosswalk.

When the patient still wants the compounded solution, get a signed ABN and bill the line with the GA modifier.

One word in the J7604 descriptor decides the claim

The official HCPCS descriptor for J7604 reads: Acetylcysteine, inhalation solution, compounded product, administered through DME, unit dose form, per gram.

One word in there settles the outcome. Compounded means a pharmacy mixed the solution instead of supplying an FDA-approved final product. That single attribute is what makes the code non-payable under Medicare.

CMS defines a compounded inhalation solution in three parts. It is not an FDA-approved preparation. It comes from a pharmacy that is not an FDA-approved manufacturer. It also involves mixing, combining, or altering ingredients for one beneficiary.

That definition is broad, so even an FDA-approved ingredient mixed with something else produces a compounded solution. When the patient receives the commercially manufactured unit dose product instead, the code is J7608, and J7608 is payable.

The diagram below follows both branches to their outcome.

Why Medicare denies J7604 on every claim

CMS Local Coverage Determination L33370 (Nebulizers) settles it in one line. Compounded inhalation solutions, the policy says, will be denied as not reasonable and necessary.

J7604 is the first code on that list, alongside J7607, J7609, J7610, and anything compounded billed under J7699. CMS repeats the point in its Medicare Learning Network material on nebulizers.

The companion CMS Nebulizers Policy Article A52466 closes the last door. It lists J7604 under the heading “ICD-10-CM Codes that DO NOT Support Medical Necessity.”

Beside that group of codes, the entry reads “all ICD-10 codes.” Every diagnosis in the code set fails, so there is no covered indication to document toward and no modifier that unlocks payment.

That distinction matters. Most denial guidance assumes the code is payable and the paperwork is at fault, but here the code itself is the problem.

A denied J7604 line is a correct adjudication rather than an error. Sending it to an appeals queue burns staff time for a result that will not change.

J7699 is not a way around it

There is one more trap worth knowing. A52466 says J7608 “may only be used for inhalation solutions which are FDA-approved,” and that compounded versions must be billed with J7699. Yet L33370 denies compounded solutions billed under J7699 too.

Follow the coding rule correctly and the claim still pays nothing. No Medicare code pays for a compounded acetylcysteine nebulizer solution.

The denial spreads to the equipment too

L33370 is explicit about this. When none of the drugs used with a nebulizer are covered, the compressor, the nebulizer, and the accessories are denied as well.

A practice dispensing only compounded acetylcysteine can lose the equipment claim alongside the drug claim.

What to do when the product is compounded anyway

• A pharmacy-compounded solution has no payable Medicare code, so either switch to the FDA-approved product or bill with a signed ABN.
• Because the denial is expected, append GA when you hold a properly executed Advance Beneficiary Notice, or GZ when you do not.
• GA transfers financial liability to the beneficiary. GZ does not, and it flags the line for review.
• A line billed without KX, GA, or GZ is rejected as missing information before medical necessity is assessed.
• Dispensing fees (G0333, Q0513, Q0514) are payable only alongside a covered inhalation drug, so a denied line earns none.

J7604 has no payment rate, J7608 does

There is no 2026 rate to look up for J7604. The code is denied as not reasonable and necessary, so Medicare publishes no DMEPOS fee schedule allowable for it.

A submitted line adjudicates at zero. Any third-party site quoting a national average is reporting billed charges or a carrier placeholder.

J7608 is the code that carries a payment rate. It sits on the DMEPOS fee schedule, is priced per gram, and is adjusted by jurisdiction. Pull the current figure for your own MAC from the CMS DMEPOS fee schedule rather than a published average.

LCD L33370 caps acetylcysteine at 74 grams per month, and quantities beyond the cap are not reasonable and necessary regardless of the diagnosis.

Reviewing payer rates quarterly is good practice, and for this code family the review is short. Confirm the current J7608 allowable for your jurisdiction.

Check that the 74 gram cap has not moved in the annual LCD update. Then make sure nothing in your formulary still routes compounded acetylcysteine to J7604.

No diagnosis code can rescue a J7604 claim

Most code guides open a section like this with a list of covered diagnoses. For J7604 the list is empty by design.

A52466 places the code under “ICD-10-CM Codes that DO NOT Support Medical Necessity” and specifies all ICD-10 codes. Adding J44.1 or E84.0 will not save the claim, and hunting for a better diagnosis is time spent on a code that cannot pay.

The diagnoses below matter for J7608, the payable code. A52466 lists 141 ICD-10-CM codes in Group 7. The table samples the respiratory diagnoses that come up most often in DME billing.

Check the full Group 7 list in the policy article before you submit, because a sample is not the policy.

The E84 pair catches practices out, so give it a second look. Group 7 includes E84.0, cystic fibrosis with pulmonary manifestations, but not E84.9, cystic fibrosis unspecified. A record documenting pulmonary involvement should be coded to E84.0.

Choosing the unspecified option turns a supportable claim into a denial, and the same logic runs down the whole list.

A diagnosis code describing the condition that necessitates nebulizer therapy has to appear on every claim for the equipment, the accessories, and the drugs. Where COPD is the reason, that usually means J44.1 or another code in the J44 range.

Check it at the point of service. Finding the problem on a remittance six weeks later costs far more to fix.

What a payable acetylcysteine claim needs on file

Documentation will not make J7604 payable, so the requirements below are what a J7608 claim needs. LCD L33370 is direct about the starting point. A Standard Written Order must reach the supplier before the claim is submitted, and billing without a completed SWO means a denial.

The LCD also restricts who may bill. Claims from entities not licensed by the state to dispense drugs are denied for lack of medical necessity.

What the initial order must contain

• Standard Written Order: beneficiary name, order date, a description or brand name of the item, quantity, and the treating practitioner’s name, NPI, and signature
• Drug detail: acetylcysteine named, with concentration, dose, frequency, and route in the order or the medical record
• Product confirmation: written evidence that the solution dispensed is the FDA-approved, non-compounded unit dose product
• Supporting diagnosis: a Group 7 ICD-10-CM code in the medical record that matches the code on the claim
• Clinical justification: practitioner documentation of persistent thick or tenacious pulmonary secretions, the covered indication in LCD L33370
• Nebulizer coverage: evidence the beneficiary has a covered nebulizer and compressor under the same policy

What every refill has to prove

• Dispensing records confirming the grams supplied per delivery, kept within the 74 grams per month maximum
• Refill requests raised no earlier than the interval the DME MAC allows, with evidence the beneficiary is nearly out
• Proof of delivery for each shipment
• Documentation of continued medical necessity and continued use
• A record of any change in product, concentration, or frequency, including a switch between compounded and FDA-approved solutions

Keeping dispensing records aligned with the units on the claim is where suppliers most often lose money. J7608 is billed per gram.

An auditor who sets 30 billed grams against a 28 gram dispensing log has found an overpayment without needing a clinical opinion. The file should let a reviewer rebuild the episode from paperwork alone.

How an acetylcysteine claim moves to payment

Acetylcysteine nebulizer solution is billed on a CMS-1500 claim form, or its electronic equivalent the 837P. The practitioner who orders nebulizer therapy does not bill the drug.

The supplier who dispenses it does, working through the DME MAC. Pabau, a practice management platform, adds claims software for billing teams, so the order, the claim, and its status stay in one system.

The claim, step by step

1. Confirm the product first. Establish whether the solution is the FDA-approved unit dose product (J7608) or a compounded one (J7604)
2. Verify eligibility and the DME benefit. Check active Medicare Part B coverage and a covered nebulizer and compressor under LCD L33370
3. Confirm enrollment and licensure. The billing NPI must be enrolled with the DME MAC, and the entity licensed by the state to dispense drugs
4. Obtain the SWO before submission. The order must reach the supplier first, not afterwards
5. Check the diagnosis against Group 7. Confirm the ICD-10-CM code on the claim appears in the A52466 list for J7608
6. Calculate units in grams. Total the grams dispensed and keep the monthly figure within 74 grams
7. Apply the right modifiers. KO for a single-drug unit dose container, plus KX, GA, or GZ
8. Submit on the CMS-1500 or 837P. Code in field 24D, units in 24G, diagnosis codes in 21A to 21L, supplier NPI in field 33
9. Retain the file. Keep the SWO, dispensing records, proof of delivery, and clinical documentation ready for audit

Which modifiers belong on the line

The KX, GA, and GZ family is not optional. A52466 states that claim lines billed without one of the three are rejected as missing information. So a technically perfect J7608 claim still fails when that modifier is absent.

The acetylcysteine crosswalk is shorter than it looks

There are exactly two acetylcysteine nebulizer codes, one compounded and one not, plus the not-otherwise-classified codes that catch the rest.

Third-party crosswalks often add J7609, and that is wrong. J7609 is albuterol, inhalation solution, compounded product, administered through DME, unit dose, 1 mg.

The drug is different and the unit of service is different, so neither one belongs in an acetylcysteine comparison.

The practical rule is short. If the acetylcysteine is FDA-approved and non-compounded, bill J7608. If it is compounded, no Medicare code pays, and the decision moves from coding to whether the patient will accept liability under an ABN.

Where acetylcysteine claims go wrong most often

Acetylcysteine denials follow a short and predictable list. Most of them are decided before the claim is built, at the moment somebody picks a code for the product in the box.

The remittance tells you which bucket a failure belongs to. CO-50, not deemed a medical necessity, is what a J7604 line returns, and it means the claim was never payable. CO-4, procedure code inconsistent with the modifier used, points at the KO, KP, and KQ rules, and that one is fixable.

Our guide to denial codes covers the rest of the set.

Other payers do not all read it the same way

Medicare’s position on J7604 is settled, but it does not bind every payer. Coverage of compounded inhalation solutions varies, and no payer publishes a blanket answer you can rely on.

What works is a process for finding out in writing, before anything is dispensed.

• Medicare Advantage: Part C plans apply national and local coverage policy as their floor, so an LCD denial carries across. Treat J7604 as non-payable unless the plan documents otherwise.
• Medicaid: coverage of compounded drugs is set state by state through the formulary and prior authorization rules. Ask the program or the managed care organization, and get the answer in writing.
• Commercial payers: policies vary by plan and usually run through prior authorization rather than a published code list. A pre-service determination naming the product is the only dependable answer.
• Secondary payers: where Medicare denies the line, there is generally no allowable for a secondary plan to coordinate against. Check how that plan treats a primary denial first.

One pattern is worth building into the workflow. For a compounded inhalation solution, no claim goes out without either a written coverage determination or a signed ABN.

Keep that determination attached to the patient record, where the billing team can see it before the product leaves the shelf.

How Pabau keeps the order and the claim together

Most failures on this policy happen upstream of the claim. The product detail lives in a pharmacy record, the order lives in the chart, and the dispensing history lives in a spreadsheet.

The biller then builds the claim from whichever of the three they can find. By the time a CO-50 comes back, nobody can say quickly whether the solution was compounded or who signed the order.

Pabau keeps the clinical record and the billing work in one system. The order, the documentation, and the claim history sit against the same patient instead of in separate tools.

Claims are prepared and submitted from that record, and their status stays visible in the same place afterwards. That shortens the time between a denial arriving and somebody understanding it.

None of that makes a compounded acetylcysteine claim payable, and no software can. What it does is put the product question in front of the team before dispensing. It also leaves a complete file behind for the claims that were payable.

Keep your nebulizer drug claims moving

Pabau’s claims management tools give billing teams one place to prepare, submit, and track claims. The order, the patient record, and the claim history stay in the same system.

Book a demo

Conclusion

J7604 is a valid HCPCS code that Medicare will not pay. LCD L33370 denies compounded inhalation solutions as not reasonable and necessary, and A52466 rules out every ICD-10 code behind them.

No fee schedule allowable sits behind the code either. Recognizing that early is worth more than any documentation improvement, because it moves the work from appealing denials to choosing the right product.

Where the patient has persistent thick or tenacious pulmonary secretions and receives the FDA-approved unit dose solution, J7608 is the code.

Keep it within 74 grams a month, support it with a Group 7 diagnosis, and bill it with KO plus KX. Where the product is compounded, the honest answer to the patient is an ABN rather than an appeal.

Keeping the order, the product detail, and the claim in one place is what makes that check quick enough to do every time. Book a demo to see how Pabau handles nebulizer drug claims from order to remittance.

Continue your research

Billing the albuterol side of the same nebulizer? HCPCS code J7613 covers the FDA-approved albuterol unit dose product and the same compounded split.

Need the equipment claim as well as the drug? HCPCS code E0570 explains how the nebulizer and compressor are covered under the same policy.

Billing the disposable supplies? HCPCS code A7003 covers the administration set that travels with every nebulizer drug claim.

Working out which denials are worth reworking? Denial management in healthcare sets out how to sort fixable denials from the ones that were never payable.

Building a DME billing workflow that survives an audit? Medical billing compliance covers documentation standards, audit readiness, and payer rule management.

Frequently asked questions